Catalyst Event
Celltrion Inc (068270) · Other
From Akros Korea Shareholder Return High Dividend Index (AKSRHD)
3/20/2026, 12:00:00 AM
Received approval from Health Canada on March 20, 2026, for the auto-injector version of 'Steqeyma' (ustekinumab biosimilar), enhancing its product lineup in the North American market. This approval is estimated to have a price impact of over 1%.
Korean Translation
2026년 3월 20일, 캐나다 보건부로부터 자가면역질환 치료제 '스테키마'의 오토인젝터 제형 허가를 획득함. 북미 시장 라인업 강화에 따라 1% 이상의 주가 영향이 예상됨.
Related Recent Events
Woori Financial Group Inc (316140) · Earnings Release
The company's Q1 2026 earnings release is scheduled for April 24, 2026, with an estimated price impact of 1% scheduled.
4/24/2026, 12:00:00 AM
NH Investment & Securities Co Ltd (005940) · Earnings Release
First quarter 2026 earnings release on April 23, 2026, is scheduled.
4/23/2026, 12:00:00 AM
Samsung Fire & Marine Insurance Co Ltd (000810) · Other
Samsung Fire & Marine Insurance announced on March 20, 2026, its decision to cancel its own treasury shares (1,363,682 common shares and 92,490 preferred shares) on March 31, 2026, scheduled. This is estimated to have a medium market impact.
3/31/2026, 12:00:00 AM
COWAY Co Ltd (021240) · Other
Annual General Meeting scheduled for March 31, 2026, where a proxy contest with activist fund Align Partners over the appointment of an audit committee member is expected. Both parties have requested a court-appointed inspector for the meeting.
3/31/2026, 12:00:00 AM
Shin Young Securities Co Ltd (001720) · Other
Announced annual cash dividend of KRW 5,000 per share. The ex-dividend date is March 30, 2026. Low importance assigned as price impact is estimated at 1-2%; scheduled
3/30/2026, 12:00:00 AM
NH Investment & Securities Co Ltd (005940) · Other
The ex-dividend date for the annual cash dividend of KRW 1,300 per share on March 30, 2026, is scheduled.
3/30/2026, 12:00:00 AM